What medications are appropriate for this patient?

Medication Management for This Patient

Without specific patient details provided, I will outline the evidence-based approach to appropriate medication prescribing based on the most recent high-quality guidelines.

Systematic Approach to Medication Selection

The foundation of appropriate prescribing requires evaluating the patient's specific conditions, therapeutic goals, and potential drug interactions before selecting any medication. 1 This systematic approach should follow these key steps:

1. Define the Patient's Clinical Problems

• Clearly identify all active medical conditions requiring treatment 1
• Assess disease severity and functional status 2
• Determine if the patient is robust (disease prevention/cure goals) or frail (symptom control/function maintenance priorities) 2

2. Establish Therapeutic Objectives

• For robust patients: aim to delay or cure disease and minimize functional impairment 2
• For frail patients: prioritize symptom control, maintaining function, and addressing quality of life 2

3. Select Appropriate Drug Therapy Based on Condition

For Chronic Coronary Syndrome (CCS):

Aspirin 75-100 mg daily is recommended lifelong in patients with prior MI, remote PCI, or evidence of significant obstructive CAD. 3

• Antianginal therapy: Beta-blockers and/or calcium channel blockers (CCBs) as first-line 3
• Add-on therapy: Long-acting nitrates or ranolazine should be considered if symptoms inadequately controlled on beta-blockers/CCBs 3
• Alternative add-on: Nicorandil or trimetazidine may be considered as second-line 3
• Post-PCI: Dual antiplatelet therapy (aspirin 75-100 mg + clopidogrel 75 mg daily) for up to 6 months is the default strategy 3

For Hypertension:

Primary agents include thiazide diuretics (chlorthalidone preferred), ACE inhibitors, ARBs, or CCBs as first-line monotherapy. 4, 5, 6

• Stage 1 hypertension with ASCVD risk ≥10%: Initiate combination therapy with nonpharmacological interventions 5
• Stage 2 hypertension: Start two agents of different classes simultaneously 5
• Preferred combinations: Thiazide + ACE inhibitor/ARB, or CCB + ACE inhibitor/ARB 7, 6
• Target BP: 120-129 mmHg systolic in patients with history of stroke/TIA 6
• Post-MI patients: Beta-blockers and RAS blockers are recommended 6
• Symptomatic angina: Beta-blockers and/or CCBs are recommended 6

Important contraindication: Simultaneous use of ACE inhibitor, ARB, and/or renin inhibitor is potentially harmful and not recommended. 4, 5

For Heart Failure:

In symptomatic HFrEF/HFmrEF, the following are recommended: ACE inhibitors (or ARBs if not tolerated) or ARNi, beta-blockers, MRAs, and SGLT2 inhibitors. 6

• HFpEF: SGLT2 inhibitors are recommended 6
• Avoid: Calcium channel blockers (except amlodipine or felodipine if required) in HFrEF 4, 5
• Avoid: Non-dihydropyridine CCBs (diltiazem, verapamil) in HFrEF 4, 5

For Atrial Fibrillation:

Direct oral anticoagulants (DOACs) are recommended in preference to VKAs for stroke prevention. 8

• Rate control: Beta-blockers, diltiazem, verapamil, or digoxin as first-choice in patients with LVEF >40% 8
• Avoid: Routine combination of beta-blockers with non-dihydropyridine CCBs due to bradycardia/heart block risk 8

4. Key Safety Considerations

Medications to Avoid or Use Cautiously:

• NSAIDs: Generally contraindicated in heart failure; can elevate BP 4, 9, 5
• Antiarrhythmics (other than amiodarone): Generally contraindicated in heart failure unless specific indication 9
• Avoid in combination: ACE inhibitor + ARB + renin inhibitor 4, 5

High-Risk Medications Requiring Monitoring:

• Anticoagulants, opioids, and antipsychotics require enhanced safety strategies 10
• Monitor for adverse drug events, particularly in older adults with multiple comorbidities 10

5. Medication Review Process

Review all medications systematically, noting history of adverse effects, need for each drug, duplication in therapy, inappropriate dose/route/schedule, current adverse effects, drug-drug interactions, and drug-disease interactions. 11

• Evaluate therapy regularly and consider discontinuation when appropriate 1
• Reassess BP control every 2-4 weeks until target achieved 5, 7
• Consider drug costs when prescribing 1

6. Special Populations

Older Adults:

• Assess for cognitive impairment, polypharmacy risks, and functional status before prescribing 2, 10
• Use tools to identify inappropriate prescribing (e.g., Beers Criteria) 12
• Balance benefits of evidence-based therapies against risks of adverse drug reactions 2, 12

7. Patient Education and Monitoring

Provide information, instructions, and warnings about medications; evaluate therapy regularly with monitoring of treatment results. 1

• Home BP monitoring is recommended to achieve better control 6
• Multidisciplinary approaches improve BP control 6
• Ensure medication reconciliation across healthcare transitions 10